Schrodinger’s Candidate? Achillion’s Sovaprevir On Clinical Hold, But Phase II Combo Trial Continues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Following findings of elevated liver enzymes in a Phase I drug/drug interaction study, FDA placed Achillion’s protease inhibitor sovaprevir on clinical hold. But the agency is allowing an ongoing Phase II combination trial with NS5A inhibitor ACH-3102 in HCV to continue, probably due in part to clean safety reads from other DDI studies with the protease inhibitor.
You may also be interested in...
Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.
Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
Indivior Reorganizing And Re-Investing In US Commercial Functions
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: